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Cancer is the second leading cause of death worldwide. Cisplatin has challenged cancer treatment;
however, resistance and side effects hamper its use. New agents displaying improved activity and more
reduced side effects relative to cisplatin are needed. In this work we present the synthesis, character-
ization and biological activities of three complexes with quinoline-substituted 2,20:60 ,200-terpyridine
ligand: [Pt(40-(2-quin)-terpy)Cl](SO3CF3) (1), [Au(40-(2-quin)-terpy)Cl](PF6)2$CH3CN (2) and [Cu(40-(2-
quin)-terpy)Cl](PF6) (3). The three complexes displayed a high antiproliferative activity in ovarian car-
cinoma cell line (A2780) and even more noticeable in a colorectal carcinoma cell line (HCT116) following
the order 3 > 2 > 1. The complexes IC50 are at least 20  lower than the IC50 displayed by cisplatin
(15.4 mM) in HCT116 cell line while displaying at the same time, much reduced cytotoxicity in a normal
dermal fibroblast culture. These cytotoxic activities seem to be correlated with the inclination angles of
2-quin unit to the central pyridine. Interestingly, all complexes can interact with calf-thymus DNA (CT-
DNA) in vitro via different mechanisms, although intercalation seems to be the preferred mechanism at
least for 2 and 3 at higher concentrations of DNA. Moreover, circular dichroism (CD) data seems to
indicate that complex 3, more planar, induces a high destabilization of the DNA double helix (shift from
B-form to Z-form). Higher the deviation from planar, the lower the cytotoxicity displayed by the com-
plexes. Cellular uptake may be also responsible for the different cytotoxicity exhibited by complexes with
3 > 2 >1. Complex 2 seems to enter cells more passively while complex 1 and 3 might enter cells via
energy-dependent and -independent mechanisms. Complexes 1e3 were shown to induce ROS are
associated with the increased apoptosis and autophagy. Moreover, all complexes dissipate the mito-
chondrial membrane potential leading to an increased BAX/BCL-2 ratio that triggered apoptosis. Com-
plexes 2 and 3were also shown to exhibit an anti-angiogenic effect by significantly reduce the number of
newly formed blood vessel in a CAM model with no toxicity in this in vivo model.
Our results seem to suggest that the increased cytotoxicity of complex 3 in HCT116 cells and its po-
tential interest for further translation to pre-clinical mice xenografts might be associated with: 1) higher
% of internalization of HCT116 cells via energy-dependent and -independent mechanisms; 2) ability to
intercalate DNA and due to its planarity induced higher destabilization of DNA; 3) induce intracellular
ROS that trigger apoptosis and autophagy; 4) low toxicity in an in vivo model of CAM; 5) potential anti-
angiogenic effect.
© 2021 The Author(s). Published by Elsevier Masson SAS. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).Choroba), ma.fernandes@fct.
ier Masson SAS. This is an open ac1. Introduction
Since the discovery of the anticancer properties of cis-
[PtCl2(NH3)2] and its approval for human use as anticancer agent,cess article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Scheme 1. Pt(II), Au(III) and Cu(II) compounds (1e3) employed in this study.
1 Electronic Supplementary Information (ESI) available online: HRMS, FT-IR,
NMR, XPRD, selected structural data, short intra- and intermolecular interactions,
Hirshfeld surface analysis, UVeVis absorption and stability experiments, UVeVis
spectra upon exposure of reducing agents, the Beer-Lambert law of 1, Plots of A0/
(AeA0) vs. 1/[DNA] of UVeVis CT-DNA titration, CD spectra of control samples, cell
viability of cisplatin, Western blot analysis, angiogenic effect of peptide controls.
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important research area [1e4]. It is believed that the use of metal-
drugs in therapy provides opportunities which are not accessible to
pure organic molecules. Despite the spectacular success of cisplatin
and its analogues carboplatin and oxaliplatin, widely applied in vast
majority of cancer treatments, the design of new biologically active
metaleorganic coordination compounds remains a great challenge.
Much more work is required to obtain agents displaying improved
activity profile and more reduced side effects relative to cisplatin
chemotherapy.
Scientific attention is currently being paid not only to platinum-
based anticancer agents but also to non-platinum anticancer
agents, particularly those with bio-essential metal ions [3e5].
Several complexes of titanium(IV), ruthenium(III) or gallium(III),
for example (h5-C5H5)2TiCl2, [InH][trans-RuCl4In2] (KP1019, In e
indazole) and Ga(quin)3 (KP46, quin e 8-quinolinol) have entered
clinical trials, while iron(III), cobalt(III), copper(II) and gold(III)
complexes have been proven to show promising antiproliferative
properties [3e7]. Also, different mechanisms of anticancer agent
actions have been revealed. A biologically active molecule can
interact with DNA strand in covalent (via alkylation or inter- and
intrastrand crosslinking, like cisplatin and its analogues) and non-
covalent mode e by groove binding (facilitated by van der Waals
interactions and hydrogen bonding), intercalation (stabilized by p-
p stacking interactions between the drug and DNA bases) or
external binding (electrostatic outside-edge stacking interactions)
[8e14]. On the other hand, complexes containing redox-active
metals may undergo both interaction with DNA and redox re-
actions, which allow them to interact with other biological mole-
cules [15]. The choice of the metal center determines the redox
activity of the drug, while the ligand is responsible for DNA
recognition [16]. Most importantly, the compounds showing
different type of DNA binding and mechanisms of action than cis-
[PtCl2(NH3)2] may induce cell death in cisplatin-resistant tumors.
In order to get further insights into the role of metal center and
ligand substitution in square-planar coordination compounds, we
have synthetized and investigated the molecular structures and
antiproliferative properties of three new complexes (Scheme 1)
with 2,20:60,200-terpyridine (terpy) ligand functionalized with 2-
quinolinyl (2-quin).
With reference to the previous results concerning biologically
active transition metal complexes bearing terpy-based ligands
[3,5,13,17e28], searching new efficient anticancer agents in this
group seems to be particularly justifiable. Chelating ability of terpy
ligands enhances the complex stability, while their planarity pro-
motes intercalative interaction of the complex with DNA due to p-
stacking between the plane of the aromatic rings and DNA base
pairs.
2. Results and discussion
2.1. Synthesis and characterization
The preparation of [Pt(40-(2-quin)-terpy)Cl](SO3CF3) (1), [Au(40-
(2-quin)-terpy)Cl](PF6)2$CH3CN (2) and [Cu(40-(2-quin)-terpy)
Cl](PF6) (3) was carried out according to the procedures given in
Scheme 2. To synthesize the complex 1, a modified two-step liter-
ature method was used [29e32]. An equimolar amounts of
[Pt(PhCN)2Cl2] and Ag(SO3CF3) were refluxed in acetonitrile solu-
tion to give an intermediate [Pt(PhCN)2(CH3CN)Cl]CF3SO3 which,
after filtration of AgCl, was used in the solvatothermal reactionwith
the 40-(2-quin)-terpy ligand. To obtain the compound 2, KAuCl4 was
refluxed with 40-(2-quin)-terpy and NH4PF6 in methanol:water (1:4
v/v) mixture, while the Cu(II) complex 3 was synthesized using a
slow diffusion technique in a test tube, where a solution of CuCl22
with NH4PF6 and a solution of 40-(2-quin)-terpy ligand were layered
on top of each other.
The compositions of 1e3 were established by X-ray analysis in
combinationwith HR-MS spectrometry, FT-IR technique and 1H and
13C NMR spectroscopy (Figures S1eS4 in ESI1). The characteristic
absorptions of 1e3 originated from stretching vibrations n(C]N,
C]C) occur in the range of 1620e1550 cm1, and they are slightly
increased in energy relative to the free ligands (see Figure S2, ESI1).
The bands associated with the stretching modes of CF3SO3 counter
anion in the IR spectrum of 1 appear at 1263 cm1 (na(SO3)),
1031 cm1 (ns(SO3)) and 637 cm1 (da(SO3)) [33], while the intense
bands near 840 cm1 and 558 cm1 in the IR spectra of 2 and 3 are
indicative of the presence of PF6 group [34]. The full assignment of
the signals in the 1H and 13C NMR spectra of the Pt(II) and Au(III)
complexes was achieved by using multidimensional techniques
1He13C HMBC, 1He13C HMQC, 1He1H COSY (Figure S3eS4 in ESI1).2.2. Solid state structures of 1e3
The perspective views of the molecular structures of 1e3
together with the atom numbering are depicted in Fig. 1, while the
Scheme 2. Synthetic route to compounds 1e3.
Table 1
Selected bond lengths [Å] and angles [] of complexes 1e3.
Bond length 1 (M ¼ Pt) 2 (M ¼ Au) 3 (M ¼ Cu)
M(1)eCl(1) 2.3046(10) 2.2563(19) 2.1835(16)
M(1)eN(1) 2.016(4) 2.028(6) 2.034(5)
M(1)eN(2) 1.934(3) 1.955(5) 1.934(4)
M(1)eN(3) 2.010(4) 2.009(6) 2.033(5)
Bond angle 1 (M ¼ Pt) 2 (M ¼ Au) 3 (M ¼ Cu)
N(1)eM(1)eCl(1) 99.21(9) 98.17(16) 101.12(14)
N(2)eM(1)eCl(1) 178.75(10) 178.25(16) 179.24(14)
N(3)eM(1)eCl(1) 98.51(9) 100.10(18) 99.61(13)
N(1)eM(1)eN(2) 81.45(14) 80.4(2) 79.64(18)
N(1)eM(1)eN(3) 162.28(13) 161.7(2) 159.27(18)
N(2)eM(1)eN(3) 80.83(14) 81.3(2) 79.63(18)
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The metal centre in the [M(40-(2-quin)-terpy)Cl]nþ (n ¼ 1 for 1
and 3, n ¼ 2 for 2) is coordinated by the chloride ion and three
nitrogen donors from 40-(2-quinolinyl)-2,20:60,200-terpyridine
ligand, and its coordination sphere is best described as a distorted
square planar (Fig. 1). By analogy to the related terpyridine tran-
sition metal complexes [35], the MeNcentral bond length is shorter
in relation to those of the outer pyridyl rings (Table 1).
It is worth noting that the square-planar geometry is typical for
Pt(II) and Au(III) complexes, but it is highly unusual for terpyridine
Cu(II) ones. To the best of our knowledge, [Cu(40-(2-furanyl)-terpy)
Cl](CF3SO3) is an unique example for which the planar conforma-
tion has been evident by the X-ray analysis so far [36]. The most
common terpyridine Cu(II) structures are [Cu(40-R-terpy)Cl2]
[37e46] and dimers [Cu2(40-R-terpy)2Cl2]X2 [47e49] (X ¼ ClO4,
PF6), generally possessing Cu(II) ions in square-pyramidal geome-
try with a long apical bond (in 4 þ 1 coordination). In the structure
of 3, the cation [Cu(40-(2-quin)-terpy)Cl]þ is ideally coplanar due to
the constraints of the Pnma space group symmetry. All the atoms
occupy the special positions c of the Pnma space group with the
multiplicity four. For 1 and 2, maximum distances from the best
plane defined by the atoms M(1), N(1), N(2), N(3) and Cl(1)
are 0.168(15)Å for N(2) in 1 and þ 0.015(2)Å for Au(1) in 2.
The distortion of the complex cations [M(40-(2-quin)-terpy)
Cl]nþ from square planar geometry has been further evaluated us-
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z109:5 .Fig. 1. The molecular structures of 1e3 together with the atom numb
3
For ideal square planar and tetrahedral structures, t04 parame-
ters are expected to take values of 0 and 1, respectively. Consistent
with the calculated t04 values, the deviation from square planar
geometry around the central atom in [M(40-(2-quin)-terpy)Cl]nþ
increases in the order 1 (t04 ¼ 0.053) < 2 (t04 ¼ 0.056) < 3
(t04 ¼ 0.060). The angular distortion of the [M(40-(2-quin)-terpy)
Cl]nþ unit from the idealized geometry is attributed to the presence
of the 40-(2-quin)-terpy ligand, which acts as chelating tridentate
and forms two fused five-member chelate rings. The N(2)eM(1)e
N(1) and N(2)eM(1)eN(3) angles vary in the range 79.63e81.45,
while the NeMeCl angles are between 98.17 and 101.12 (Table 1).
All they deviate from 90 expected for a square planar geometry. In
the case of 1, the terpy framework is approximately planar, with the
dihedral angles between the mean planes of the central pyridine
and terminal aromatic rings equal 3.4(1) and 3.5(1), while 2-quin
unit is inclined at 26.0(1) to the central pyridine. Remarkably, in 2
and 3, the whole 40-(2-quin)-terpy ligand adopts a planar structure.ering. Displacement ellipsoids are drawn at 50% probability level.
K. Choroba, B. Machura, A. Szlapa-Kula et al. European Journal of Medicinal Chemistry 218 (2021) 113404The dihedral angle between the central pyridine and peripheral
pyridyl ring is 2.4(3) in 2 and 0 in 3, while the dihedral angle
between the central pyridine and 2-quin substituent equals to
3.2(3) in 2 and 0 in 3 (Table S1, ESI1). The ligand planarity is
beneficial in the context of possible intercalative interaction of the
complex with DNA due to p-stacking between the plane of the
aromatic rings and DNA base pairs.
The differences concerning the twisting of the pendant het-
erocycle subsistent in relation to central pyridine ring in 1e3 seem
to be a consequence of the crystallographic symmetry and crystal
packing effects. As shown in Fig. 2 and ESI materials1 (Figure S6 and
Tables S2eS4), the packing arrangements for 1e3 demonstrate a
large contribution of p/p interactions in all the structures as well
as Cl/p (in 1), CeH/F, CeH/N and CeH/Cl (in 2 and 3).
In 1 and 3, the neighbouring cations [M(40-(2-quin)-terpy)Cl]þ
are stacked in a head-to-tail orientation with two alternating dis-
tances 3.3903(2) and 3.7139(2) Å between adjacent complexes in 1
and one spacing of 6.6271(0) in 3. The Pt/Pt distances below 3.5 Å
are indicative for effective metallophilic (dz2edz2 orbital) in-
teractions [17,51,52]. As shown by Hirshfeld surface analysis
[53e55], Pt/Pt interactions covers 1.1% of all the surface contacts
(see ESI1, Figures S7 and S8). In the structure 2, two fluorine atoms
(from two different hexafluorophosphate anions) are weakly
bonded to the Au(III) ions, occupying the axial coordination sites
(Figure S9, ESI1). The formed AueF distances of 3.031(9) and
2.883(8) Å are shorter than the sum of van der Waals radii of gold
and fluorine (3.13 Å) [56,57], giving rise to a pseudo-octahedral
coordination around gold(III) in 2 as in the previously reported
[AuCl(40-R1-terpy)](PF6)2 [58], [AuCl(40-R2-terpy)](PF6)2 [58],
[AuCl(terpy)](BF4)2 [59], [Au(C6F5)(h3-terpy)](PF6)2 [57],
[Au(bpMe)Cl2][PF6] [60], [Au(bpOMe)Cl2][PF6] [60], [AuCl(bmpa-
H)](BF4) [61] and [Au(R-pyoxPh)Cl2][PF6]0.5[AuCl4]0.5 [62]. In 3, the
shortest distance between the Cu(II) ion and fluorine atom of
hexafluorophosphate anions is 4.702(0) Å.
2.3. UVevis spectroscopy studies
The electronic absorption spectra of 1e3 (5  105 M) were
collected in CH3CN, DMSO and 10 mM phosphate buffered saline
(PBS, pH 7.4) once every 4 h over 48 h at room temperature
(Figures S10eS14 and Table S5 in ESI1). For all the complexes, strong
absorptions in the high-energy region (250e350 nm) are attributed
to p/p* and n/p* intraligand (IL) transitions within the coor-
dinated terpyridyl ligand. Low energy absorption bands
(350e450 nm) in the spectra of 1 and 2 are attributed to metal-to-
ligand charge-transfer (MLCT) [31,63e68] and ligand-to-metal
charge-transfer (LMCT) [57,69e73], respectively. For Cu(II) com-




2 , dyz, dxz/dx2-y2 and dz2/dx2-y2 copper(II) transitions
[74e76] (Figures S10eS11 in ESI1).
Except for 1 in PBS and 2 in DMSO, there was no change in the
absorbance profile of the designed complexes over 48 h, indicating
their stability in solution (Fig. 3 and Figures S12eS14 in ESI1). PBS
solution of 1 (5  105 M) shows a noticeable broad absorption
band at 488 nm, which can be attributed to metal-metal-to-ligand
charge-transfer (MMLCT; ds*(Pt2)/p*(terpy)] transitions arising
from the presence of Pt/Pt and/or pp stacking interactions,
favoured in polar environment. The observed suppression of
absorbance intensity of PBS solution of 1 in the entire spectral range
is thus a consequence of aggregation process, as evidenced by the
deviation from the Beer-Lambert Law for highly concentrated so-
lutions of 1 (Figure S15, ESI1) [77e81]. In the case of solution with
lower concentration of 1 (5  106 M), the MMLCT absorption
disappears and the absorbance bands remain constant over 48 h
(Figure S12, ESI1). Also, addition of DMSO to the PBS solution of 14
leads to a decrease of MMLCT absorbance intensity (Figure S16,
ESI1).
Stability experiments for compound 2 in DMSO revealed a
decrease in the intensity of the LMCT, most likely due to chloride-
DMSO exchange reaction, in agreement with the results reported
for gold(III) complexes bearing hydroxyl- and amino-quinoline li-
gands [82]. However, the partial hydrolysis of the complex cation
[Au(40-(2-quin)-terpy)Cl]2þ cannot be excluded [83].
Upon addition of the stoichiometric amount of glutathione or
sodium ascorbate (reducing agents abundant in most cancer cells
cytoplasm) to buffer solutions of 1e3, only UVeVis spectra of 3
remain unaltered (supplementary1 Figure S17). The stability of 1
and 2 is strongly diminished by the reducing agents, as reflected by
rapid changes in their absorbance profile, with loss of the LMCT/
MLCT bands. Lack of the formation of absorbance typical of colloidal
gold(0) between 500 and 600 nm in UVeVis spectrum of 2 upon
exposure of glutathione and sodium ascorbate may signal conver-
sion from gold(III) to gold(I) [84,85].
2.4. DNA binding
Complex 1 has a higher inclination of the 2-quin unit (26.0(1))
to the central pyridinewhen compared to complex 2 and complex 3
[3.2(3) and 0, respectively] (Table S1 in ESI1). As planarity of li-
gands might affect interaction of complexes with their targets,
namely DNA [16], we further studied the in vitro interaction be-
tween our complexes and calf-thymus DNA (CT-DNA). To study the
mode of interactions between DNA and complex molecules, three
different instrumental techniques were used, that are UVeVis ab-
sorption titration, ethidium bromide displacement assay and cir-
cular dichroism spectroscopy.
2.4.1. UVevis spectrophotometric DNA titration
In this method, drugeDNA interactions are studied by compar-
ison of UVeVisible absorption spectra of the free drug and
drugeDNA complexes. Compounds which bind with DNA through
intercalative mode concerning a stacking interaction between the
planar aromatic chromophore and the base pairs of DNA usually
results in hypochromism, along with or without a small red shift in
the wavelength. The hyperchromic effect is associated with the
external contact (electrostatic binding) or to the major/minor
grooves of the DNA [6,7,86e91].
As depicted in Fig. 4, the addition of increasing amounts of CT-
DNA to the solution of 2 in PBS (25 mM) results in a decrease in
the absorption intensity of the MLCT band at 357 nm. On the
contrary, the intraligand (IL) absorbance at 282 nm shows hyper-
chromism up to r ¼ 5 (where r is the [DNA]/[complex] mixing ra-
tio), and upon further addition of CT-DNA, the band intensity is
decreasing. Such observations may indicate the presence of
different modes of interactions between DNA and complex mole-
cules. The hyperchromic effect is most probably due to the presence
of charged cations which bind to DNA via electrostatic attraction to
the phosphate group of the DNA, while hypochromism is indicative
for intercalative binding [6,7,86e91]. Notably, the second effect
seems to be strongly preferred at higher DNA concentrations. The
dual-functionmode of action of 2 is also supported by the isosbestic
point at 333 nm disappearing for [DNA]/[2] > 5, and it is reflected in
a clear deviation from linearity A0/(A-A0) vs. 1/[DNA] plot for the
absorbance data at 357 nm [88]. The intrinsic binding constant Kb of
2, estimated from the intercept to-slope ratio of A0/(A-A0) vs 1/
[DNA] plot was 1.20  104 M1.
Different modes of interactions with DNA are clearly shown also
in the case of the complex 1 in PBS (5 mM). The hypochromism of
the absorption bands at 330 and 283 nm, isosbestic points at 409
and 359 nm and appearance of new band at 436 nm, are indicative
Fig. 2. View of the supramolecular packing of complexes 1e3.
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planar aromatic chromophore and the base pairs of DNA and co-
valent interaction via the loss of the chloride ions [6,7,86e91].
The addition of increasing amounts of CT-DNA to the solution of
3 in PBS (25 mM) results in a decrease in the absorption intensity of5
both CT and IL bands at 332 and 279 nm, which could suggest
intercalation mode of binding. However, a clear deviation from
linearity A0/(A- A0) vs. 1/[DNA] plot for the absorbance data at
332 nm is indicative for presence of different interactions between
the complex molecules and DNA (Figure S18 in ESI1).
Fig. 3. UVeVis spectra 1e3 in DMSO (a) and PBS (b) (5  105 M) recorded once every 4 h over 48 h at room temperature.
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Ethidium dibromide (EB) is a standard intercalating agent. Due
to strong interactions between ethidium bromide and adjacent
DNA base pairs, EB shows the enhanced fluorescence in the pres-
ence of DNA. Any compound that intercalates into DNA equally or
more strongly than EB replaces it from the EB-DNA adduct, leading
to decrease or quenching of the fluorescence emission [92]. Binding
interaction of 1e3 to CT-DNA was estimated using ethidium bro-
mide (EB) displacement assay in PBS buffer with the constant
concentration of CT-DNA and EB ([DNA] ¼ [EB] ¼ 50 mM) and
varying the concentrations of the complexes.
The changes in the fluorescence intensity of EBeCT-DNA adduct
with increase of concentrations of the tested compounds 1e3 are
shown in Fig. 5. All the three complexes show no emission in this
region.
For each complex, fluorescence intensity decreases as the
compound concentration increases, indicating that EB molecules
are displaced from their DNA binding sites and replaced by the
appropriate complex. The complexes 1, 2 and 3 quenched 33%, 58%
and 14% of the fluorescence of the EBeCT-DNA adduct, respectively.
The calculated DNA binding constants (Table S6 ESI1) were
found to increase in the order 3 (Kapp ¼ 1.53  106 M1) < 1
(Kapp ¼ 5.71  106 M1) < 2 (Kapp ¼ 3.45 107 M1), indicating that
complex 2 competes with EB bound to CT-DNA much more effi-
ciently than 1 and 3. The lack of the strong correlation with the
tendency observed for the binding constants Kb (Table S6) can be
explained by the simultaneous presence of different modes of in-
teractions between DNA and longer incubation time in EB
displacement assay, which seems to encourage the intercalative
mode of binding.
2.4.3. Circular dichroism spectroscopy
To take further insights into the nature of the interactions of
complexes with DNA, a circular dichroism analysis was performed
using calf thymus DNA (CT-DNA) in the presence of the increasing
concentrations of the complexes or in the presence of DMSO (con-
trol). With this technique it is possible to detect conformational6
alterations of DNA using circularly polarized electromagnetic light
(Fig. 6) [93].
The circular dichroism spectra of the B-form of CT-DNA presents
a negative peak at 245 nm, correlated with the right-handed hel-
icity of DNA, and a positive peak at 275 nm, due to base-pair
stacking [93,94]. The incubation of CT-DNA with increasing con-
centrations of the three complexes results in a change of intensity
and/or profile of both CD bands (Fig. 6). A hypochromic effect is
generally correlated with intercalation of ligands causing the
elongation of the double helix [93,95], which can be observed for all
complexes for the 275 nm peak. Interestingly, CD of CT-DNA incu-
bated with 25 mM of complex 3 presents a positive peak at 245 nm
accompanied by a slightly negative peak near 280 nm, which are
more typical of Z-form of DNA (Fig. 6C). CT-DNA incubated with
25 mMof complex 1 displays CD spectra with the loss of the 275 nm
positive peak while maintaining the 254 nm peak, while CT-DNA
incubated with 25 mM of complex 2 presents both peaks (Fig. 6A
and B). Additionally, an extrinsic CD with different amplitudes is
also observed in CT-DNA e complexes spectra’s around
350e390 nm for 3 (more pronounced) and 2 and 350e450 nm for 1,
respectively (Fig. 6). Since complexes 1, 2 and 3 do not have a sig-
nificant CD activity at these wavelength range (Supplementary1
Figure S19), these peaks are probably the result of the interaction
between complexes and CT-DNA. The appearance of this extrinsic
CD peakwas correlatedwith the intercalation of ligand to DNA [96].
These results suggest that the secondary structure of DNA is effi-
ciently destabilized by all the three complexes (Fig. 6). Neverthe-
less, complex 3 seem to induce a higher destabilization compared
to the other complexes, which might be correlated with the
planarity of ligand in 3.
Despite complex 2 competes with EB bound to CT-DNA much
more efficiently than 1 and 3, after a 30 min incubation (Fig. 5), it
seems that a longer incubation period (6 h)might influence CT-DNA
structure in a different manner (Fig. 6). Nevertheless, our CD results
agree that all complexes can interact in vitro with CT-DNA (Figs. 4
and 5), but complex 3 induces an increased change in the helicity
of DNA (conversion of a right to a left-handed form).
Fig. 4. UVevis spectra of PBS solution of complex 1 (5 mM), 2 (25 mM) and 3 (25 mM) in the absence and presence of increasing amounts of CT-DNA. The arrows show the changes
upon increasing amounts of CT-DNA.
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Next, we decided to evaluate the biological effect of the com-
plexes within human cells. Considering that, the antiproliferative
effect of the complexes 1e3 was determined in two cancer cells,
A2780 (derived from ovarian carcinoma) and HCT116 (derived from
colorectal carcinoma) and in normal dermal fibroblasts using the
MTS assay after a 48 h incubation (Fig. 7). It is possible to observe a
concentration dependent decrease in cellular viability of complexes
1e3 (Fig. 7).
The highest cytotoxic effect was displayed by complex 3 (lower
IC50) in the HCT116 cell line (Fig. 7 and Table 2). The cytotoxicity of
the complexes follows the trend 3 > 2 > 1 in the three cell lines
studied (Fig. 7 and Table 2), despite the IC50 values in colorectal
cancer cells seem to be more similar for all complexes compared to
the IC50 values observed in A2780 cells or in normal fibroblasts.
Indeed, complexes 2 and 3 are much more cytotoxic to A2780 and
fibroblasts compared to complex 1 (Table 2).
Nevertheless, all three complexes showed higher cytotoxicity in
HCT116 cancer cell line and lower cytotoxicity in normal dermal
fibroblasts (Fig. 7 and Table 2). Particularly, complex 1 seems to be7
the less cytotoxic to normal cells (IC50 > 100 mM). Using similar
terpy frameworks, previously published Au(III) complexes dis-
played higher cytotoxicity than similar Cu(II) and Pt(II) complexes,
while in this work, complex 3, a Cu(II) complex, displayed higher
cytotoxicity than its Au(III) counterpart, complex 2 (Fig. 7 and
Table 2). Our results also seem to support previous published
works, inwhich the terpy framework displays higher cytotoxicity in
HCT116 cell line when compared to A2780 cancer cell line and
normal dermal fibroblasts [97,98].
The lower solubility of complex 1 in PBS may contribute to its
lower cytotoxicity (Figs. 3 and 7, Table 2); however, we have
observed a decrease of cell viability with the increase of complex 1
concentration (Fig. 7). Importantly, differences in cytotoxicity
appear to reflect deviations from planar symmetry of the com-
plexes. Complex 1, which displays lower cytotoxicity, has a higher
inclination of the 2-quin unit (26.0(1)) to the central pyridine
when compared to other complexes (Fig. 7, Table 2 and Table S1 in
ESI1). Interestingly, the differences in the cytotoxicity displayed by
complexes 2 and 3 also appear to follow the inclination of 2-quin
unit towards the central pyridine [3.2(3) and 0, respectively]
(Fig. 7, Table 2 and Table S1, ESI1). The planarity of the ligands could
Fig. 5. Emission spectra (lex ¼ 510 nm) of EBeCT-DNA in PBS buffer with the increasing concentration of 1e3 (0e50 mM for 1, 3 and 0e20 mM for 2). The inset shows the Stern-
Volmer plots for corresponding complexes.
Fig. 6. CD-spectra of CT-DNA (12.5 mM) incubated for 6 h at 37 C with increasing 0, 12.5 and 25 mM of complex 1 (A), 2 (B) or 3 (C). Results were normalized to vehicle controls
(DMSO 0% 2.5% and 5%, respectively).
K. Choroba, B. Machura, A. Szlapa-Kula et al. European Journal of Medicinal Chemistry 218 (2021) 113404affect the cytotoxicity of the complexes by affecting their ability to
interact with some of their targets, namely DNA. Indeed, when we
analyze the results from CD it seems that after intercalation8
complex 3, the planar one and the one demonstrating a more
cytotoxic effect (Fig. 7), induces a higher destabilization of the
double helix (Fig. 6). The results presented in Figs. 4e6 suggest that
Fig. 7. Antiproliferative effect of complexes 1e3 in A2780 and HCT116 cancer cell lines and in normal dermal fibroblasts determined by the MTS assay. DMSO 0.1% was used as a
vehicle control. The results are presented as mean ± SD of three independent assays. The symbol * indicates a p-value < 0.05.
Table 2
Relative IC50 values (mM) of complexes 1e3 in A2780 and HCT116 cancer cell lines
and in normal dermal fibroblasts.
Cell lines 1 (mM) 2 (mM) 3 (mM)
A2780 7.12 ± 0.92 0.38 ± 0.06 0.37 ± 0.08
HCT116 0.61 ± 0.06 0.24 ± 0.12 0.21 ± 0.07
Fibroblasts IC50 > 100 14.34 ± 0.57 7.2 ± 0.96
Fig. 8. Internalization of complexes 1e3 as evaluated by ICP-AES determination of Pt,
Au and Cu, respectively, in the cellular fraction of HCT116 cancer cells after 4 h
exposure of cells to 20 the respective IC50 concentrations at 4 C and 37 C. Results
were normalized to the DMSO control and to the respective complex concentration
added to cells.
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the cytotoxicity displayed by the complexes (Fig. 7 and Table 2). We
should always be careful when correlating in vitro and cell-based
assay. Indeed, we analysed the effect of complexes in CT-DNA
in vitro (without cells). In a complex media/environment such as
cells, more interactions with different targets might exist, meaning
that the amount of complex reaching the nucleus might be too low
to see a real effect on DNA. Nevertheless, the higher stability of
complex 3 in the presence of reducing agents (as cytoplasm is a
more reducing environment) may contribute to reach its biological
target (namely DNA) more easily and the slightly higher cytotox-
icity when compared to complex 2 (Fig. 7 and Figure S17, ESI1).
Considering all this cell-associated complexity it is important to
further understand the differential cytotoxicity displayed by com-
plexes 1, 2 and 3 in HCT116 cell line. The internalization of com-
plexes within cells is also an important point to consider as the % of
complexes internalized in cells might correlate with their cyto-
toxicity. In that respect, HCT116 cells were incubated with the three
complexes for 4 h at two different temperatures, 4 C and 37 C, and
inductively coupled plasma atomic emission spectrometry (ICP-
AES) used to quantify the % of metal in the cellular fraction (cells
incubated with complexes compared to cells in the absence of
complexes (Fig. 8). Since copper is an essential metal normalization
of results to cells copper levels in the absence of complex 3 is
important. It is important to note also, that due to the low IC50 of
the complexes and the sensitivity of ICP-AES technique, a higher
concentration of complexes 1e3 (20 IC50) was used (ensuring
measurable amounts of Pt, Au and Cu by ICP-AES). Due to the high
toxicity associated with the exposure of cells for 48 h to these
concentrations, internalization was assessed after a 4 h incubation
time (Fig. 8).
Whenwe observe the % of normalized intracellular Pt, Au and Cu
at 37 C a correlation of internalization and cytotoxicity is clearly
observed with 3 > 2 > 1 (Figs. 7 and 8). Indeed, at 37 C, 13%, 26%
and 33% of complex 1, 2 and 3, respectively is observed in cells
(Fig. 8). Interestingly, when we performed the same assay but at
4 C (a reduction of cell metabolic activity and energy dependent
uptake is observed) there is a significative reduction of the intra-
cellular % of 1 and 3 (13%e7% for complex 1, and 33%e18% for
complex 3) (Fig. 8). On the contrary, for complex 2 no effect in the %
of internalization is observed when we reduce the temperature of9
incubation (Fig. 8). These results might indicate that 2 might enter
cells via an energy-independent process, while 1 and 3 enter cells
mediated in part by an energy-dependent process (Fig. 8).
Considering that in our experimental conditions, the IC50 of
cisplatin in HCT116 and A2780 cell lines is 15.4 and 3.4 mM,
respectively (supplementary1 Figure S20), the complexes here
described deserved great attention due to the low IC50, particularly
in HCT116 cell line. Indeed, other published metallic complexes
with terpyridine ligands display IC50 values in the range of
0.3e17.3 mM in the HCT116 cell line while in the A2780 cell line IC50
values vary from 0.95 to 16.2 mM when effective [46,97,98]. The
complexes here described have IC50 within the lower range of the
interval for the HCT116 cell line (Fig. 7, Table 2). Therefore, this cell
line was chosen to further characterize the biological mechanisms
involved in the observed loss of viability induced by complexes
1e3.2.5.1. Apoptosis induction after exposure of HCT116 cells to IC50
concentrations of complexes 1-3
The loss of cell viability observed in the presence of complexes
1e3 deserved further exploitation and cell death process was
further studied. As a first approach, apoptosis, a programmed cell
death, was determined by flow cytometry using the Annexin V-
Alexa fluor 488/PI double staining after 48 h of exposure of
HCT116 cells to IC50 concentrations of complexes 1e3 (Fig. 9).
With this method, it is possible to distinguish cells in early
apoptosis (labelledwith Annexin V-Alexa fluor 488 stain only), cells
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PI stains), cells in necrosis (labelled with PI stain only) from normal
viable cells (not labelled with any of the stains). It is possible to
observe a statistically significant increase in apoptotic cells exposed
to complex 3 in both early and late apoptosis (Fig. 9). There is an
6.5 increase of apoptotic cells (both early and late) in HCT116 cells
exposed to compound 3 when compared to the DMSO control
(2.85% and 0.44%, respectively) (Fig. 9) Exposure to the other
complexes revealed a non-statistically increase in apoptotic
HCT116 cells, 0.67% and 0.55%, respectively. Induction of apoptosis
was also observed in other complexes bearing terpy ligands [97,98].
There was also a small decrease of HCT116 cells in necrosis,
although not statistically significant, in cells exposed to complex 1
(1.91%), complex 2 (2.15%) and complex 3 (1.56%) when compared
to the cells exposed to the DMSO control (2.49%) (Fig. 9).
2.5.2. Determination of BAX and BCL-2 protein expression by
western-blot
As a good marker of apoptosis induction is the increase in the
ratio of pro-apoptotic protein BAX versus anti-apoptotic protein
BCL-2 [99]. Considering that, HCT116 cells were exposed to IC50
concentrations of the complexes for 48 h and the levels of the pro-
apoptotic protein BAX and the anti-apoptotic protein BCL-2 were
determined by western-blot (WB) (Fig. 10 and Figure S21).
Our results show a statistical increase of the BAX/BCL-2 ratio for
the three complexes (Fig. 10C), in agreement with the induction of
apoptosis in Fig. 9. Despite we were expecting a higher ratio BAX/
BCL2 for complex 3, it should be mentioned that despite both
methods are evaluating the trigger of apoptosis, they target different
features in thewhole the process. Indeed, flow cytometry allow us to
quantify phosphatidylserine on the external cell membrane (trans-
location triggered in early phases of apoptosis) (Fig. 9) while WB
were used to quantify the levels of BAX and BCL-2 (pro-apoptotic and
anti-apoptotic proteins, respectively) that are involved in the control
of mitochondrial membrane permeability [99]. Under stress condi-
tions, cytoplasmatic BAX undergoes a conformational change that
causes its translocation to the mitochondrion outer membrane and
trigger pore formation and release of cytochrome C into the cyto-
plasm an event that precedes activation of caspases [99]. Moreover,
recently, in a study describing novel oxovanadium complexes,
cellular detachment, probably due tomembrane destabilization, was
identified as a contributing factor to underestimate apoptosis when
using Annexin V-Alexa fluor 488/PI assay by flow cytometry [100].
We cannot discard that this may also be occurring with cells exposedFig. 9. Induction of apoptosis in HCT116 cells exposed to IC50 concentrations of complexes 1
0.1% (v/v) and cisplatin 15.4 mMwere used as vehicle and positive controls, respectively. The
a p-value < 0.05.
10to complexes 1e3 for 48 h and another reason for the small values
discrepancies between methods.
Since the induction of apoptosis, via this intrinsic pathway, is
associated with a destabilization of mitochondrial membrane po-
tential, we subsequently evaluated the effect of the complexes on
mitochondrial membrane potential.
2.5.3. Evaluation of the mitochondrial membrane potential (DJM)
changes
To evaluate the integrity of the mitochondrial membrane,
changes in its membrane potential were evaluated using the
cationic dye JC-1 that as a monomer exhibits green fluorescence.
The negative potential of the inner mitochondrial membrane (high
DJM) induces aggregation of the JC-1 dye within mitochondria
and results in a red shift of the dye’s fluorescence (from 532 to
590 nm). Therefore, cells with permeable mitochondriawill display
a lower red/green fluorescence ratio.
The results show a significant dissipation of the mitochondrial
membrane potential in HCT116 cells exposed to the complexes 1e3
for 48 h (Fig. 11), These results agree with previous data from BAX/
BCL2 ratio (Fig. 10) and that exposure to complexes 1e3 trigger
apoptosis through the intrinsic pathway [99].
2.5.4. Autophagy induction after exposure of HCT116 cells to IC50
concentrations of complexes 1-3
Considering the high cytotoxicity induced by the complexes we
were expecting a higher level of cell death. Besides apoptosis other
types of programmed cell death have been described, namely
autophagy. Autophagy has been implicated with cytotoxicity
associated with cisplatin and novel vanadium and platinum coor-
dination complexes [100,101]. The induction of autophagy in
HCT116 cell line after exposure to complexes 1e3was investigated,
by the identification of cells carrying autophagosomes after 48 h
exposure to IC50 concentrations of the complexes (Fig. 12).
There is an increase in the autophagic HCT116 cells due to
exposure to complexes 1e3, when compared to the DMSO 0.1%
control, (Fig. 12). Complexes 1, 2 and 3 presented 4.4%, 9.3% and
14.0% of cells in autophagy, respectively, which represent increases
of 2.6  , 5.5  and 8.2  when compared with autophagic cells in
the DMSO control (1.7%) (Fig.12). The level of autophagy induced by
complex 3 was almost similar to the level induced by rapamycin,
the positive control (Fig. 12). The autophagic cell death agrees with
the cytotoxicity of complexes (Fig. 7 and Table 2), apoptosis by flow
cytometry (Fig. 9) and internalization (Fig. 8) with 3 > 2 > 1.e3 for 48 h evaluated by flow cytometry using the Annexin V/PI double staining. DMSO
results are presented as mean ± SD of three independent assays. The symbol * indicates
Fig. 10. Expression of BAX (A) and BCL-2 (B) proteins in HCT116 cells incubated for 24 h with complex 1, 2, 3 or 0.1% (v/v) DMSO (control). (C) Apoptotic index of HCT116 cells,
calculated by BAX/BCL-2 ratio. The symbol * indicates a p-value < 0.05.
Fig. 11. Evaluation of mitochondrial membrane potential membrane (DJM) changes
in HCT116 cells exposed to IC50 concentrations of complexes 1e3 for 48 h evaluated by
flow cytometry using JC-1 staining. DMSO 0.1% (v/v) and cisplatin 15.4 mM were used
as vehicle and positive controls, respectively. The aggregate (red fluorescence)/
monomer (green fluorescence) ratios were normalized for the DMSO control ratio. The
results are presented as mean ± SD of three independent assays. The symbol * in-
dicates a p-value < 0.05.
Fig. 12. Induction of autophagy in HCT116 cells exposed to IC50 concentrations of
complexes 1e3 for 48 h evaluated by flow cytometry using the Autophagy assay
(Abcam). DMSO 0.1% (v/v) was used as solvent control and cisplatin 15.4 mM and
rapamycin 50 nM were used as positive controls. The results are presented as
mean ± SD of three independent assays. The symbol * indicates a p-value < 0.05.
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apoptosis and autophagic cell death in cells exposed to complexes
1e3, particularly when exposed to complex 3. This may be due to
the presence of the terpy ligand in all complexes but the planarity of
3 might provide an additional feature for increased internalization
and cytotoxicity. In a recent work, terpyridine derived compounds
were demonstrated to simultaneously induce apoptosis and auto-
phagy in cancer cell lines exposed to them [102].2.5.5. Intracellular reactive oxygen species (ROS) in HCT116 cell line
exposed to complexes 1-3
Increased intracellular ROS have been correlated with the pro-
grammed cell death observed in cancer cell lines exposed to Au(III),
Pt(II) and Cu(II) complexes bearing terpy ligands and were inves-
tigated in HCT116 exposed to IC50 concentrations of complexes 1e3
(Fig. 13) [97,98].
Exposure to complexes 1e3 induced an increase of 4.9  ,
7.1  and 11.4  , respectively, in intracellular ROS when compared
with the DMSO control (Fig. 13). Complex 3, bearing a Cu(II) centre,
induces higher levels of intracellular of ROS than complexes 1 and
2, which seems to be correlated with the higher levels of inter-
nalized Cu(II), the increased apoptosis and autophagy in
HCT116 cells exposed to complex 3 (Figs. 9 and 12). It should be
noted that despitemitochondria is themain site for ROS production11within cells, we did not observe an increased mitochondria mem-
brane destabilization with complex 3 meaning that the increase in
ROS levels should be triggered by the complex. To validate this
theory, HCT116 were pre-incubated for 1 hwith N-acetyl-L-cysteine
(NAC) a ROS scavenger [103]. Indeed, pre-incubation of cells with
NAC, reduced the amount of ROS produced in HCT116 cell line by
21,7%, 45.8% and 63,5% in cells exposed to complex 1, 2 and 3,
respectively (Fig. 13). Moreover, we further analysed if the trigger of
apoptosis was due to ROS (Figure S22, ESI1). Pre-incubation with
NAC reduced apoptosis in HCT116 exposed to complex 1, 2 and 3 by
91%, 85% and 96% respectively (Figure S22). Taken together these
results confirm previous observations in which ROS production is
correlated with apoptosis and autophagic cell death induction in
cancer cells exposed to metallic complexes bearing terpy ligands
[97,98] and that complex 3 increased cytotoxicity is due to 1)
increased internalization, 2) its ability to induce intracellular ROS
that triggers autophagy and apoptosis.2.5.6. Ex-ovo chorioallantoic membrane (CAM) in vivo assay
Ex-ovo chorioallantoic membrane (CAM) assay is a well-known
in vivo model to assess cytotoxicity and also potential agents that
can modulate angiogenesis [104]. To evaluate in vivo toxicity and
pro-angiogenic or anti-angiogenic potential of complexes 1e3 was
Fig. 13. Production of reactive oxygen species (ROS) in HCT116 cells exposed to IC50
concentrations of complexes 1e3 for 48 h evaluated by flow cytometry. DMSO 0.1% (v/
v) was used as solvent control and cisplatin 15.4 mM and H2O2 50 mM were used as
positive controls. HCT116 cells were also pre-incubated for 1 h at 37 C with 5 mM of
N-acetyl-cysteine (NAC) before incubation with complexes (indicated in the
Figure with þNAC). The results are presented as mean ± SD of three independent
assays. The symbol * indicates a p-value < 0.05.
Fig. 14. Percentage of newly formed vessels in ex-ovo CAMs after 24 h exposure to IC50
concentrations of complexes 1e3. At least 5 independent chicken embryos experi-
ments were used to construct violin bars representing the distribution density and
average of the normalized newly formed vessels. Normalization was performed using
the percentage of tertiary veins obtained after exposure to DMSO 0.1% (v/v) to which
the dotted line at 100% refers to. The results are presented as mean ± SD of five in-
dependent assays. The symbol * indicates a p-value <0.05.
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the IC50 concentrations of each complex and all newly formed
vessels were counted at 0 h, 24 h and compared with the DMSO
vehicle controls (Fig. 14).
Interestingly, no chicken embryos deaths were observed for the
tested concentrations in all 5 independent CAM experiments,
indicating that despite these concentrations can induce HCT116
loss of cell viability, they do not induce toxicity in this in vivomodel.
What is more, complexes 2 and 3 show a high anti-angiogenic
effect on the CAMs of chicken embryos, with a reduction of the
average of newly formed vessels to 59.7% and 56.7%, respectively,
when compared to DMSO control (Fig. 14), which might be highly
interesting for their application in cancer context avoiding tumor
angiogenesis, a process that is critical for tumor growth and met-
astization [105]. On the contrary, complex 1 seems to induce a
slight increase of the average of newly formed vessels (Fig. 14). Pro-
angiogenic and anti-angiogenic controls were also included in
supplementary1, Figure S23.
Taken together these results seem to indicate that complex 2
and 3 have an antiproliferative effect in colorectal cancer cells by
inducing apoptosis (mostly 3) and autophagy due to the generation
of ROS and that there are able to inhibit the formation of newly
blood vessels.
2.6. Conclusions
This work presents the synthesis, chemical and biological
characterization of three complexes of Pt(II), Au(III), Cu(II) bound to
40-(2-quin)-terpy ligand.
All complexes displayed cytotoxic potential in A2780 and,
mainly in HCT116 cancer cell lines following the order 3 > 2 > 1. The
complexes IC50 are at least 20  lower than the IC50 displayed by
cisplatin (15.4 mM) [100] in HCT116 cell line while displaying at the
same time, much less cytotoxicity in normal dermal fibroblasts.12Although the lower stability of complex 1 in PBS could explain the
lower cytotoxicity of complex when compared to the others, the
cytotoxic results seem to be correlated with the inclination angles
of 2-quin unit to the central pyridine. CD data seems to indicate that
complex 3, more planar, induces a high destabilization of the DNA
double helix (shift from B-form to Z-form). Higher the deviation
from planar, the lower the cytotoxicity displayed by the complexes.
Cellular uptake may be also responsible for the cytotoxicity
exhibited by complexes and while complex 2 seems to be passively
internalized, complex 1 and 3 might enter cells via energy-
dependent and -independent mechanisms. Complexes 1e3 were
shown to induce ROS that might be associated with the increased
apoptosis and autophagy. Moreover, all complexes dissipate the
mitochondrial membrane potential leading to an increased BAX/
BCL-2 ratio that triggered apoptosis. Complexes 2 and 3 were also
shown to exhibit an anti-angiogenic effect by significantly reduce
the number of newly formed blood vessel in a CAM model with no
toxicity in this in vivo model.
Our results seem to suggest that the increased cytotoxicity of
complex 3 and its potential interest for translation to pre-clinical
mice xenografts might be associated with: 1) higher % of inter-
nalization of HCT116 cells via energy-dependent and -independent
mechanisms; 2) its ability to intercalate DNA and due to its
planarity induced higher destabilization of DNA (as measured
in vitro by CD), that all together 3) induce intracellular ROS that
trigger apoptosis and autophagy.3. Experimental
3.1. Materials
The metal salts and solvents used for the synthesis were
commercially available and were used without further purification.
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grade, while the solvents for spectroscopic measurements were of
HPLC grade. The ligand 40-(2-quin)-terpy was prepared according
the modified method employed in our previous studies [106e108],
and its purity was checked with 1H NMR and elemental analysis
(see Figure S5, ESI1).
3.2. Synthesis
3.2.1. Synthesis of [Pt(40-(2-quin)-terpy)Cl](SO3CF3) (1)
[Pt(PhCN)2Cl2] (0.24 g, 0.5 mmol) dissolved in acetonitrile
(30 ml) was added to a 10 ml solution of Ag(CF3SO3) (0.13 g,
0.5 mmol). The reaction mixture was heated under reflux for 12 h,
after which the white precipitate of AgCl was removed by filtration.
A solution of ligand 40-(2-quin)-terpy in acetonitrile (0.18 g,
0.5 mmol) was added to the filtrate. The resulted mixture was
heated in a solvatothermal reactor under atmospheric pressure for
24 h and then gradually cooled for another 24 h. The X-ray quality
orange crystals were obtained directly from mother liquor.
[Pt(4′-(2-quin)-terpy)Cl](SO3CF3) (1). Yield 65%. HRMS (ESI):
calcd for C24H16ClN4Ptþ [M]þ 590.0708 found 590.0710. IR (cm¡1):
439(w), 453(w), 475(w), 516(m), 572(m), 637(s), 663(w), 696(s),
700(s), 714(w), 748(m), 768(m), 784(s), 829(m), 869(w), 908(w),
1031(s), 1050(w), 1140(s), 1163(s), 1224(s), 1264(s), 1275(s),
1333(w), 1374(w), 1416(m), 1433(m), 1476(m), 1505(m), 1555(m),
1594(m), 1610(s), 2926(w), 3026(m), 3084(w), 3462(w). UVeVis
(CH3CN 5 £ 10¡5 M/nm, (ε £ 103/M¡1 £ cm¡1): 406 (8.52), 389
(7.11), 353 (10.77), 332 (24.35), 313 (20.89), 283 (34.34), 264 (32.10).
1H NMR (400MHz, DMSO) d 9.16 (s, 2H, HB2), 8.72 (d, J¼ 8.0 Hz, 2H,
HA4), 8.70e8.63 (m, 3H, HA1, C2), 8.46 (d, J ¼ 8.6 Hz, 1H, HC3), 8.41
(dt, J ¼ 7.8, 1.2 Hz, 2H, HA3), 8.18 (d, J ¼ 8.4 Hz, 1H, HC6), 8.08 (d,
J¼ 7.9 Hz,1H, HC9), 7.91 (t, J¼ 7.6 Hz,1H, HC7), 7.82 (t, J¼ 6.6 Hz, 2H,
HA2), 7.77 (t, J¼ 7.5 Hz, 1H, HC8). 13C NMR (100MHz, DMSO) d 158.3
(CA5), 155.0 (CB1), 151.7 (CA1), 151.3 (CB3), 151.3 (CC1), 147.8 (CC4),
143.1 (CA3), 138.7 (CC2), 131.4 (CC7), 130.0 (CC6), 129.8 (CA2), 129.0
(CC8), 128.7 (CC5), 128.6 (CC9), 126.7 (CA4), 122.2 (CB2), 119.8 (CC3).
3.2.2. Synthesis of [Au(40-(2-quin)-terpy)Cl](PF6)2
. CH3CN (2)
KAuCl4 (0.19 g, 0.5 mmol) dissolved in methanol/water (1:4 v/v)
(50 ml) was added to the methanolic solution of ligand 40-(2-quin)-
terpy (0.18 g, 0.5 mmol) and refluxed for 2 h. After that, an aqueous
solution of NH4PF6 (0.20 g, 1.2 mmol) was added, and the resulting
mixture was heated for another 2 h. The solution was allowed to
evaporate in a hood at room temperature, which gave an orange
microcrystalline precipitate of 2. The X-ray quality crystals were
grown by recrystallization of the precipitate from acetonitrile.
[Au(4′-(2-quin)-terpy)Cl](PF6)2. CH3CN (2). Yield 45%. HRMS
(ESI): calcd for C24H16ClN4Auþ [M]2þ 592.0724 found 592.0726. IR
(cm¡1): 559(s), 688(w), 741(w), 783(m), 840(s), 1040(w), 1053(w),
1103(w), 1172(w), 1250(w), 1266(w), 1317(w), 1339(w), 1364(w),
1418(m), 1438(m), 1488(m), 1508(w), 1557(m), 1568(m), 1604(s),
3074(w), 3445(w). UVeVis (CH3CN 5 £ 10¡5 M/nm, (ε £ 103/M¡1
£ cm¡1): 374 (21.00), 362 (23.09), 297 (21.87), 288 (22.03), 275
(22.69), 239 (43.88), 227 (52.84). 1H NMR (400 MHz, CD3CN) d 9.41
(s, 1H, HB2), 9.20 (dd, J¼ 6.0, 1.2 Hz,1H, HA1), 8.82 (dd,1H, HA4), 8.75
(dt, J ¼ 7.9, 1.3 Hz, 1H, HA3), 8.71 (d, J ¼ 8.7 Hz, 1H, HC2), 8.48 (d,
J ¼ 8.6 Hz, 1H, HC3), 8.34 (d, J ¼ 8.5 Hz, 1H, HC6), 8.17e8.10 (m, 2H,
HA2, C9), 7.99 (t, J ¼ 7.7 Hz 1H, HC7), 7.83 (t, J ¼ 7.6 Hz 1H, HC8). 13C
NMR (100 MHz, CD3CN) d 159.6 (CA5), 158.3 (CB3), 153.9 (CB1), 153.5
(CA1), 150.4 (CC1), 149.1 (CC5), 148.2 (CA3), 139.7 (CC2), 132.5 (CC7),
132.4 (CA2), 131.1 (CC6), 130.6 (CC8), 130.4 (CA4), 130.1 (CC4), 129.1
(CC9), 126.0 (CB2), 120.4 (CC3).
3.2.3. Synthesis of [Cu(40-(2-quin)-terpy)Cl](PF6) (3)
A solution of ligand 40-(2-quin)-terpy (0.04 g, 0.1 mmol) in13CH2Cl2/CH3OH (1:1 v/v) was poured into a glass test tube and a neat
mixture of CH2Cl2/CH3OH was carefully layered on the ligand so-
lution. Then, the methanolic solution of CuCl2$2H2O (0.1 mmol,
0.02 g) mixed with NH4PF6 (0.25 mmol, 0.04 g) was layered on the
above mixture. The test tube was sealed and the solutions were
allowed to diffuse slowly. After about two weeks, needle-like green
X-ray quality crystals of 3 were obtained.
[Cu(4′-(2-quin)-terpy)Cl](PF6) (3). Yield 12%. HRMS (ESI):
calcd for C24H16ClN4Cuþ [M  Cl]þ 458.0354 found 458.0358. IR
(cm¡1): 414(w), 483(w), 557(s), 657(w), 690(w), 738(w), 781(m),
840(s), 928(w), 1021(m), 1038(w), 1099(w), 1147(w), 1165(w),
1251(w), 1262(w), 1307(w), 1338(w), 1380(w), 1418(m), 1438(m),
1478(m), 1506(w), 1553(m), 1566(m), 1606(s), 1620(s), 3068(w),
3106(w), 3437(m). UVeVis (CH3CN 5 £ 10¡5 M/nm, (ε £ 103/M¡1
£ cm¡1): 697 (1.30), 329 (26.57), 291 (33.88), 279 (37.27), 270
(37.57), 228 (53.35).
3.3. Instrumentation
The IR spectra were recorded on a Nicolet iS5 spectrophotom-
eter in the range 4000e400 cm1 using the KBr pellets technique.
High resolution mass spectrometry analyses were performed on a
Waters Xevo G2 Q-TOF mass spectrometer (Waters Corporation)
equipped with an ESI source operating in positive-ion modes. Full-
scan MS data were collected from 100 to 1000 Da in positive ion
mode with scan time of 0.5 s. To ensure accurate mass measure-
ments, data were collected in centroid mode and mass was cor-
rected during acquisition using leucine enkephalin solution as an
external reference (Lock-Spray™), which generated reference ion at
m/z 556.2771 Da ([MþH]þ) in positive ESI mode. The accurate mass
and composition for the molecular ion adducts were calculated
using the MassLynx software (Waters) incorporated with the in-
strument. The NMR spectra were recorded using Bruker Avance
400 MHz spectrometer in dimethyl sulfoxide-d6 ((CD3)2SO) for 1
and in acetonitrile-d3 (CD3CN) for 2. Chemical shifts (d) are re-
ported in parts per million (ppm) and referenced to residual solvent
peak ((CD3)2SO: 1H d ¼ 2.50 ppm, 13C d ¼ 39.52 ppm, CD3CN: 1H
d ¼ 1.94 ppm, 13C d ¼ 118.26 ppm). Coupling constants (J) are re-
ported in Hz. The peak multiplicity is designated by a singlet (s),
doublet (d), triplet (t), doublet of triplets (dt), and multiplet (m).
Homonuclear correlation spectroscopy was performed using 2D
COSY experiments, while heteronuclear correlation spectroscopy
was done on the basis of HMQC or HMBC (long-range) experiments.
3.4. X-ray crystallography
The crystallographic data and refinement details are given in
Table 3. The X-ray diffraction datawas collected bymeans of Oxford
Diffraction four-circle diffractometer Gemini A Ultra equipped with
Atlas CCD detector and using graphite monochromated MoKa ra-
diation (l ¼ 0.71073 Å) at room temperature. Diffraction data
collection, cell refinement and data reduction were performed us-
ing CrysAlisPro software [109]. The structures were solved with
SHELXS-2014 and refined with SHELXL-2014 [110,111], using full-
matrix least-squares on F2. The non-hydrogen atoms were
refined anisotropically while hydrogen atoms were placed in
calculated positions and refined using idealized geometries (riding
model) with fixed isotropic displacement parameters (for aromatic
rings: Uiso(H) ¼ 1.2 Ueq(C), d(CeH) ¼ 0.93 Å; for methyl:
Uiso(H) ¼ 1.5 Ueq(C), d(CeH) ¼ 0.96 Å). The methyl group was
allowed to rotate around its local threefold axis. CCDC 1824952,
2053808, and 2053807 contain the crystallographic data for 1e3
and can be obtained free of charge from The Cambridge Crystallo-
graphic Data Centre at www.ccdc.cam.ac.uk/getstructures. Powder
X-ray diffraction (PXRD) measurements were performed on a
Table 3
Crystal data and structure refinement.
Name 1 2 3
Empirical formula C25H16ClN4PtF3O3S C26H19AuClN5F12P2 C24H16ClCuN4F6P
Formula weight 740.02 923.82 604.37
Temperature [K] 295.0(2) 295.0(2) 295.0(2)
Wavelength [Å] 0.71073 0.71073 0.71073
Crystal system Monoclinic Monoclinic Orthorhombic
Space group P21/n P21/n Pnma
Unit cell dimensions [Å,] a ¼ 7.02890(18) a ¼ 7.9118(2) a ¼ 15.3579(8)
b ¼ 16.7405(4) b ¼ 29.5090(1) b ¼ 6.6271(4)
c ¼ 20.3049(7) c ¼ 13.0714(3) c ¼ 22.7715(16)
a ¼ 90 a ¼ 90 a ¼ 90
b ¼ 95.322(3) b ¼ 95.179(3) b ¼ 90
g ¼ 90 g ¼ 90 g ¼ 90
Volume [Å3] 2378.92(12) 3039.31(11) 2317.7(2)
Z 4 4 4
Density (calculated) [Mg/m3] 2.066 2.019 1.732
Absorption coefficient [mm1] 6.160 5.136 1.198
F(000) 1424 1776 1212
Crystal size [mm] 0.07  0.11  0.23 0.03  0.19  0.25 0.06  0.07  0.57
q range for data collection [] 3.4 to 25.24 3.4 to 25.05 3.5 to 25.05
Index ranges 8  h  9 9  h  8 17  h  18
23  k  21 27  k  35 7  k  7
23  l  28 15  l  15 24  l  27
Reflections collected 16071 16007 9293
Independent reflections 5695 5380 2242
Completeness to 2theta 99.7 99.7 99.6
Min. and max. transm. 0.5168 and 1.0000 0.3015 and 1.0000 0.7581 and 1.0000
Data/restraints/parameters 5695/0/343 5380/0/425 2242/0/217
Goodness-of-fit on F2 1.065 1.073 1.032
Final R indices [I > 2s(I)] 0.0313 (wR ¼ 0.0578) 0.0434 (wR ¼ 0.0977) 0.0524 (wR ¼ 0.1321)
R indices (all data) 0.0496 (wR ¼ 0.0660) 0.0558 (wR ¼ 0.1030) 0.0720 (wR ¼ 0.1400)
Largest diff. peak and hole [e Å3] 0.635 and 0.871 1.410 and 1.370 0.803 and 0.442
CCDC number 1824952 2053808 2053807
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(l ¼ 1.5418 Å), in which the X-ray tube was operated at 40 kV and
30 mA ranging from 5 to 40. The experimental diffraction pattern
was compared with the theoretical one generated using single
crystal X-ray data (Figure S24, ESI1).
3.5. Spectroscopy and stability
The UVeVis spectra were obtained using Nicolet Evolution 220
in acetonitrile, DMSO and Dulbecco’s Modified Phosphate Buffered
Saline (PBS, pH 7.4, 130 mM NaCl, Sigma Aldrich) solutions in the
range 220e1000 nm. The stability of the compounds in solution of
acetonitrile, DMSO and PBS was checked by measuring the spectra
of the sample (50 mM) once every 4 h for 48 h at room temperature.
Stability of 1e3 in the presence of biologically important reducing
agents was tested by means of the UVeVis monitoring. PBS mix-
tures of the tested complex (50 mM) with reduced glutathione
(50 mM or 1 mM) or sodium ascorbate (50 mM) were measured
every 20 min for 6 h at room temperature.
3.6. DNA-binding
The experiments were carried out in PBS at room temperature.
The concentration of calf thymus DNA (CT-DNA, Sigma Aldrich) was
determined by measurement of UVeVis absorbance at 260 nm
(A260), using Beer-Lambert law with ε260 ¼ 6600 M1 cm1 as the
CT-DNA molar absorption coefficient [112]. The ratio A260/A280 of
the solutionwas in the range 1.85e1.90, indicating that the CT-DNA
was sufficiently free of protein [113]. Stock solution of CT-DNA was
stored at 4 C and used in less than 4 days. Concentrated stock
solutions of metal complexes were prepared by dissolving the
complex in 0.1 ml of DMSO and diluted with PBS to suitable con-
centrations for all the experiments.143.6.1. UVevis spectrophotometric DNA titration
The electronic absorption titrations of complexes with CT-DNA
were carried out on ThermoScientific NanoDrop OneC UVeVis
spectrophotometer with use of l ¼ 1 cm cuvette holder in 37 C.
The complexes were dissolved in PBS in constant concentrations
(5 mM for 1 and 25 mM for 2 and 3) andwere titratedwith increasing
concentrations of CT-DNA for various r ([DNA]/[complex]) ratios
until full binding was achieved. After each addition of CT-DNA, the
mixture was magnetically stirred and incubated for 8 min before
the spectra were recorded. The equal amounts of CT-DNA were
added to both the complex and the reference solutions to eliminate
the absorbance of CT-DNA itself. The obtained data was analysed










where A and A0 are the absorbances of the complex with and
without DNA, respectively, and εG and εH-G are molar extinction
coefficients of the complex in its free and bound forms. The binding
constants Kb were calculated from linear plots of A0/(AeA0) vs 1/
[DNA] by the ratio of intercept to the slope (Figure S18).
3.6.2. Ethidium bromide displacement assay
Fluorescence quenching experiments were carried out on
Edinburgh FLS-980 spectrophotometer using ethidium bromide
(EB, Sigma Aldrich) fluorescence displacement assay. Equimolar
amount of EB and CT-DNA solutions were mixed at room temper-
ature and incubated for 2 h in the dark. The tested complex was
then titrated into the formed EBeCT-DNA adduct and incubated for
additional 30 min. The final concentration of the EBeCT-DNA
adduct was 50 mM and the concentration of the complexes varied
from0 to 50 mM. Fluorescence spectra of the samples were obtained
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quenching data was further analysed according to the linear Stern-
Volmer equation (3), which was used to calculation of the binding
constant Kapp (4):






where I0 and I are the fluorescence intensity in the absence and
presence of the complexes; KSV is the Stern-Volmer quenching
constant; [Q] is the concentration of the complexes; [Q1/2] is the
concentration of the complex causing 50% reduction in the fluo-
rescence intensity; KEB ¼ 1  107 M1; [EB] ¼ 5  105 M.
3.6.3. Circular dichroism
Circular dichroism spectra were performed after incubation of
12.5 mM calf thymus DNA (CT-DNA, Thermo Fisher Scientific) with
0, 12.5 and 25 mM of complex 1, 2 or 3. As solvent controls, 12.5 mM
calf thymus DNA was incubated with 0, 2.5 and 5% DMSO. All
samples were incubated in 5 mM tris-HCl pH 7.0 with 50 mM NaCl,
for 6 h at 37 C. The screening of each sample was performed in
triplicate in a Chirascan qCD from AppliedPhotophysics (Surrey,
United Kingdom) using a 1 cm (1 mL) quartz cuvette, ranging from
230 to 600 nm. CD spectra were performed at BIOLAB (UCIBIO,
Caparica). The CD spectra of the complexes were also acquired after
incubation of 25 mM of complex 1, 2 or 3, and DMSO 5% (vehicle
control) in 5 mM tris-HCl pH 7.0 with 50 mM NaCl, for 6 h at 37 C.
3.7. Biological studies
3.7.1. Cell culture
A2780 (Merck, Darmstadt, Germany) and HCT116 cancer cell
lines and normal dermal fibroblasts (American Type Culture
Collection, ATCC, Manassas, VA, USA), were maintained as previ-
ously described [117,118]. RPMI 1640 medium was used to culti-
vated A2780 cell lines and DMEM, Dulbecco’s Modified Eagle
medium, was used to cultivate HCT116 cells and fibroblasts. Media
were supplemented with 10% (v/v) fetal bovine serum, FBS, and
with PenStrep solution 1% (v/v) (all media and supplements from
Thermo Fischer Scientific, Waltham, MA, USA). Cells were incu-
bated in a humidified atmosphere with 5% CO2 (v/v) at 37 C, at all
times.
3.7.2. Viability assays
Cells were cultivated in 96-well plates at a density of
7.5  105 cells/ml and incubated for 24 h prior to incubation with
several concentrations of complexes 1e3 dissolved in culture me-
dia. DMSO 0.1% (solvent control) and cisplatin (positive control)
were used as internal controls in all replicates. Cell cultures were
incubated for 48 h before the CellTiter 96® Aqueous Non-
Radioactive Proliferation assay (Promega, Madison, WI, USA) was
used to determine the cellular viability (MTS assay) [117]. The Tecan
microplate reader, Infinite M200 (Tecan, M€annedorf, Switzerland)
was used to read absorbance at 490 nm and the analyses of dose
response curves and the determination of the half maximal
inhibitory concentration (IC50) was performed with the GraphPad
Prism 8.2.1 software (GraphPad Software, La Jolla, CA, USA).
3.7.3. ICP-AES
Cellular uptake of these complexes 1e3 was determined by
inductively coupled plasma atomic emission spectrometry (ICP-
AES) was used to determine the amount of molecular Pt, Au and Cu
that remained in the supernatant after exposure of HCT116 cells for154 h to IC50 concentrations of complexes 1e3 incubated at 4 C and
37 C. HCT116 cells were seeded into 25 cm2 T-flasks (5  106 cells
per flask) and incubated for 24 h at 37 C. Then fresh culture media
was added with IC50 concentrations of the complexes, and cells
were further incubated for 4 h at 4 C or 37 C. DMSO 0.1% (v/v) was
used as vehicle control. After 4 h incubation, the supernatant was
recovered and fresh acqua regia (3:1 HCl:HNO3) was added to su-
pernatants and cells were incubated o.n. in a hood at RT. HCT116
cells without any treatment were used to provide biological matrix
to perform Pt, Au and Cu standards. ICP-AES was performed as a
paid service in Laboratorio de Analises/LAQV.3.7.4. Analysis of apoptosis induction in HCT116 cell line evaluated
with the annexin V-Alexa fluor 488/PI double staining assay
As previously described, HCT116 cells were seeded in 6-well
plates at a density of 1  105 cells/ml, incubated for 24 h and
then incubated for another 48 h with IC50 concentrations of com-
plexes 1e3 dissolved in DMEM media [117,119]. HCT116 cells sam-
ples were also pre-treated with 5 mM N-acetyl cysteine (NAC)
before removal of culture media and incubation with the com-
plexes. Cells treated with DMSO 0.1% and cisplatin 15.4 mM were
used as vehicle and positive controls, respectively. After 48 h in-
cubation, cells were washed with PBS 1X, treated with Tryple Ex-
press (ThermoFisher Scientific), washed again with PBS 1X and
incubated for 15 min at room temperature with 10 mg/ml propi-
dium iodide and Annexin V-Alexa fluor 488 assay solution. Cells
were then processed in an Attune acoustic focusing flow cytometer
and the respective Attune Cytometric Software 2.1 (ThermoFisher
Scientific) was used to collect and analyze experimental results.3.7.5. Western blot for apoptotic index determination
The western-blot analysis for BAX and BCL-2 protein expression
quantification followed the same procedure described before ([120]
with few modifications. Briefly, 4  106 HCT116 cells were incu-
bated in 25 cm2 T-flasks for 24 h. Afterwards, the medium was
replaced by fresh medium supplemented with 0.1% (v/v) DMSO, or
the IC50 of complex 1, 2 or 3. After 48 h, cell monolayer was washed
three times with PBS, scraped from the surface with PBS and
centrifuged at 500g for 5min.Whole protein extract was obtained
as described before [121]. The membrane was incubated for 1 h
with fresh 5% non-fat milk in 1X TBST buffer (50 mM Tris, 150 mM
NaCl and 0.1% (v/v) Tween 20, pH ~7.5) to block non-specific protein
bidding. Then, each nitrocellulose membrane was exposed to
different primary antibody in 5% non-fat milk in TBST, namely anti-
Bax (1:5000; Abcam, United Kingdom) and anti Bcl-2 (1:1000;
Sigma, St. Louis, EUA) and was left to incubate for 1 h at RT, with
constant agitation. Concluded this incubation, the membrane was
washed three times with 1X TBST buffer with agitation for 5 min at
RT. The same procedure abovewas also employed to themembrane
incubation with the secondary antibody (1:3000, Anti-mouse IgG,
horseradish peroxidase (HPR)-linked Antibody or 1:2000, Anti-
rabbit IgG, HPR-linked Antibody; Cell Signalling Technology, USA).
All membranes were stripped with stripping buffer (0.1 M glycine,
20 mM magnesium acetate and 50 mM potassium chloride) and,
then, re-incubated with anti-b actin (1:5000; Sigma, St. Louis, EUA)
as a control for further normalization of the results. To detect the
protein bands, a WesternBright ECL subtract (Advansta, USA) was
prepared and membranes incubated for 5 min. Sequentially, the
film was exposed to the membrane, on a dark room. The quantifi-
cation of proteins was determinate by densitometry using Image J
software. The BAX and BCL-2 protein band intensities were
normalized to the intensities of the total protein of the respective
band after staining of the membrane with Ponceau S stain (Pierce)
and then to the values of DMSO treated samples.
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changes due to exposure to complexes 1-3
As described elsewhere, HCT116 cells were plated at
7.5  105 cells per ml in 6-well plates, incubated for 24 h. Fresh
medium was then added containing IC50 concentrations of com-
plexes 1e3. Cells exposed DMSO 0.1% (solvent control) and cisplatin
15.4 mMwere also used as controls. After 48 h incubation, cells were
washed with PBS 1X, treatedwith Tryple Express and washed again
with PBS 1X prior to incubationwith JC-1 dye, 5,50,6,60-tetrachloro-
1,10,3,30-tetraethylbenzimidazolylcarbocyanine iodide (JC-1,
Abnova Corporation, Walnut, CA, USA) following the recommen-
dations of the manufacturer (20 min at 37 C) [122]. The fluores-
cence of cells was then measured by flow cytometry using an
Attune acoustic focusing flow cytometer (ThermoFisher Scientific)
in the BL-1 (“green”) and BL-2 (“red”) filters and data was collected
with the respective software. Fluorescence ratios were normalized
to the DMSO control.
3.7.7. Analysis of autophagy induction in HCT116 cell line evaluated
with the autophagy assay
HCT116 cells were cultivated in 6-well plates at a density of
1  105 cells/ml and incubated for 24 h prior to exposure to IC50
concentrations of complexes 1e3. DMSO 0.1% was used as solvent
control and cisplatin 15.4 mM and rapamycin 50 nM were used as
positive controls. After 48 h incubation, HCT116 cells were washed
with PBS 1X, treated with Tryple express and washed again with
PBS 1X before the Autophagy Assay Kit (Abcam, Cambridge, UK)
was used according to the manufacturer’s instructions. The kit uses
a cationic amphiphilic tracer dye that specifically labels pre-
autophagosomes, autophagosomes and autolysosomes that are
present in cells undergoing autophagy [100]. After staining cells
were screened in an Attune acoustic focusing flow cytometer and
the experiment informationwas treated with the respective Attune
Cytometric Software 2.1 (ThermoFisher Scientific).
3.7.8. Production of reactive oxygen species (ROS) in HCT116 cell
line exposed to complexes 1-3
HCT116 cells were seeded in 6-well plates at a density of
1 105 cells/ml and incubated initially for 24 h, before another 48 h
incubationwith IC50 concentrations of complexes 1e3. Cell samples
were pre-treated with 5 mM N-acetyl cysteine (NAC) before
removal of culture media and incubation with the complexes. As
controls, cells treated with DMSO 0.1% (vehicle control), cisplatin
15.4 mM and H2O2 50 mM (positive controls) were also used. Cells
were washed with PBS 1X before treatment with Tryple express
and washed twice with PBS 1X before incubation with of 2,7-
dichlorodihydrofluorescein diacetate (H2DCF-DA) 10 mM. Cells
were then incubated for 30min at 37 C before being analysed in an
Attune acoustic focusing cytometer and respective software
(ThermoFisher Scientific) according to previously described pro-
tocols [100,117]. The ROS induced removal of acetate groups from
H2DCF-DA by intracellular esterases will turn this compound
fluorescent and identify ROS production within HCT116 cells.
3.7.9. Toxicity and anti- or pro-angiogenic potential of complexes of
1e3 determined by ex-ovo CAM assays
As described previously the ex-ovo chorioallantoic membrane
(CAM) assaywas performed to evaluate the effect of complexes 1e3
on the formation of novel blood vessels in the chicken embryo
[122,123]. Briefly, of chicken embryos in weighing boats were
incubated for 24 h (embryo stabilization) before IC50 concentra-
tions of complexes 1e3, dissolved in PBS, were placed in the centre
of O-rings and were incubated for 24 h at 37 C. Images were taken
at time point 0 h and 24 h and newly formed blood vessels (tertiary
veins) were counted as described in the literature [120,122]. For16control purposes it was also included DMSO 0.1% in PBS and anti-
angiogenic and pro-angiogenic peptides [122]. The o-ring distri-
bution in the chick embryos was assigned to ensure that each
embryowas challengedwith DMSO 0.1% and to prevent duplication
of the same complex distribution scheme in different chicken
embryos tested. This ex-ovo assay complies with the “3Rs policy”
for animal experiment and is in accordance with Directive 2010/63/
EU of the European Parliament for the protection of animal models
for scientific purposes.
3.8. Statistical analysis
All results are presented as Mean ± SD from at least three in-
dependent experiments unless otherwise stated. One or two-way
ANOVA or Student’s t-test were used to determine statistical sig-
nificance (p < 0.05) using the GraphPad Prism 8.2.1 software
(GraphPad Software, San Diego, CA, USA).
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